OmniScience and INmune Bio partner to enhance decision-making in Alzheimer's clinical trials using Vivo's genAI-powered platform.Quiver AI SummaryOmniScience and INmune Bio have announced a partnership...
Alzheimer’s Drug Market Faces Urgent Need for Innovative Therapies Beyond Big Pharma These Small-Cap Biotech Stocks Lead the Charge with Disruptive Approaches to Treating Alzheimer’s Alzheimer’s...
Small biotech firms like Cassava Sciences, INmune Bio, and Annovis Bio are developing innovative Alzheimer’s treatments, disrupting big pharma’s dominance in the $13.7B market. For those targeting...
Alzheimer’s Drug Market Faces Urgent Need for Innovative Therapies Beyond Big Pharma These Small-Cap Biotech Stocks Lead the Charge with Disruptive Approaches to Treating Alzheimer’s Alzheimer’s...
INMB earnings call for the period ending June 30, 2022.
Company to Host Conference Call Today, August 3, at 4:30pm ET...
Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, July 27, 2022 (GLOBE NEWSWIRE) -- INmune Bio, Inc....
Alzheimer's Association International Conference ("AAIC") – Systems Biology of Alzheimer's Disease Panel on August 4, 2022 Moderated by Jeffrey Cummings,...
In pre-clinical models of trastuzumab resistant MUC4 HER2+ breast cancer, treatment with INB03™ decreases MUC4 expression, reverses resistance to...
BOCA RATON, FL., May 23, 2022 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on...